Qu Biologics Welcomes Gastroenterologist Dr. Remo Panaccione to IBD Advisory Team

Home » Status Update » Qu Biologics Welcomes Gastroenterologist Dr. Remo Panaccione to IBD Advisory Team

Vancouver, British Columbia – December 4, 2014 – Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore normal immune function in the targeted diseased organ, is pleased to welcome gastroenterologist Dr. Remo Panaccione to its Inflammatory Bowel Disease (IBD) advisory team.

Qu Biologics’ IBD advisory team provides guidance and oversight of Qu Biologics’ IBD studies, including a randomized, placebo-controlled clinical trial of its investigational treatment, QBECO SSI, for Crohn’s disease, which is currently enrolling patients, and a planned Phase 2 study in ulcerative colitis.

Qu Biologics’ CEO Dr. Hal Gunn stated, “Dr. Remo Panaccione is a respected international expert in inflammatory bowel disease and his clinic has grown to become one of the leading IBD clinical care and research units in the world. We are very pleased to welcome him to our advisory team.”  He added, “IBD affects an estimated 1 in 150 Canadians, and there is a major unmet medical need to develop safe and effective treatments for these diseases. Unlike current IBD treatments that suppress immune function, Qu Biologics’ SSIs are designed to stimulate the body’s innate immune response and restore normal immune function.”

Qu Biologics’ Crohn’s disease clinical trial is a randomized, double-blinded, placebo-controlled trial recruiting 60 participants with moderate-to-severe Crohn’s disease from Canada and the U.S. The trial involves the use of investigational treatment QBECO SSI, derived from components of inactivated bacteria, which aims to stimulate a normal innate immune response to reverse the chronic inflammation underlying Crohn’s disease. More information about the trial can be found at www.quibd.com.

Primary endpoint results from Qu’s Crohn’s disease clinical trial are expected in Q2 2015. Qu Biologics is also planning to initiate a Phase 2a clinical trial of QBECO SSI in ulcerative colitis in the first half of 2015.

Biography of Dr. Remo Panaccione
Dr. Panaccione is currently a Professor of Medicine at the University of Calgary and the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary as well as Director of Gastroenterology Research for the Division of Gastroenterology and Hepatology.  He is a recognized international expert in the diagnosis, management, and treatment of inflammatory bowel disease. Dr. Panaccione sits on many editorial boards and serves as a reviewer for the New England Journal of Medicine, Gastroenterology, Gut, APT, and Inflammatory Bowel Diseases. He has lectured across North America on various topics in inflammatory bowel disease and has delivered over 175 lectures in the last five years. He has been elected to the International Organization of IBD (IOIBD) and has received the highest award, the Finkelstein Award, for this contribution to the field of IBD by Crohn’s and Colitis Canada.  Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993.  He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota.  He joined the faculty of Medicine at the University of Calgary in 1999.

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to restore the body’s normal immune response. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many conditions including cancer and immune-related diseases. The company is currently recruiting participants for a Phase 1/2 placebo-controlled, randomized clinical trial in Crohn’s disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours.  For more information, visit www.qubiologics.com.

For more information regarding this press release, contact:

Julie Jang
Director, Communications
Qu Biologics Inc.
Phone:  604.734.1450 ext.41491
Email: media@qubiologics.com

Posted on